Oppenheimer 将 ArriVent BioPharma 上调至“跑赢大盘”，目标价为 39 美元，表明有 39.39% 的上涨空间。 Oppenheimer upgraded ArriVent BioPharma to "outperform" with a $39 price target, indicating a 39.39% upside.

Oppenheimer将其对ArriVent生物药厂(NASDAQ: AVBP)的评分提升为“优异”, 将价格目标从35.00美元提高到39.00美元, Oppenheimer has upgraded its rating for ArriVent BioPharma (NASDAQ: AVBP) to "outperform," raising the price target from $35.00 to $39.00, indicating a potential 39.39% upside. 高盛也将其目标从28.00美元提高到38.00美元,而HC Wainwright则将其目标提高到36.00美元。 Goldman Sachs also increased its target from $28.00 to $38.00, while HC Wainwright raised its target to $36.00. 大多数分析家将股票评为“买家”,机构所有权占9.48%。 Most analysts rate the stock as a "buy," and institutional ownership stands at 9.48%. 该公司的重点是发展有针对性的癌症治疗。 The company focuses on developing targeted cancer therapies.